Core Business Focus

The company's core competency lies in developing integrated diagnostic platforms that combine benchtop or portable analyzers with dedicated reagent test cartridges or strips. This "system" approach—pairing instrumentation with proprietary consumables—is a common and effective business model in the IVD sector, as it generates recurring revenue through consumable sales while ensuring quality and compatibility across the diagnostic workflow.

Micropoint Biotechnologies applies several key technologies in its product development, including:

• Fluorescence immunoassay (FIA) technology, which uses fluorescent-labeled antibodies to quantitatively measure the concentration of target analytes in a sample.
• Immunochromatographic (lateral flow) assay technology for rapid qualitative and semi-quantitative detection.
• Dry chemistry and related methods for biochemistry analysis at the point of care.

These technologies allow the company to offer testing across multiple clinical categories using small sample volumes such as whole blood, serum, plasma, or urine, with results available in a matter of minutes.

Product Categories

Micropoint Biotechnologies offers a range of diagnostic products organized around clinical testing needs. The primary areas addressed by its product lines include:

Cardiac Markers

Rapid tests for cardiac biomarkers are among the most important POCT applications, since timely results are critical in the evaluation of chest pain and suspected acute coronary syndromes. The company provides quantitative assays for markers such as troponin I (cTnI), creatine kinase-MB (CK-MB), myoglobin, and NT-proBNP or BNP, which assist clinicians in the rapid triage and management of cardiac patients.

Inflammation and Infection Markers

Micropoint Biotechnologies offers tests for markers of inflammation and infection, including C-reactive protein (CRP), high-sensitivity CRP (hs-CRP), procalcitonin (PCT), and serum amyloid A (SAA). These markers help distinguish between bacterial and viral infections, guide antibiotic use, and monitor systemic inflammatory responses.

Diabetes and Metabolic Testing

Products in this category include glycated hemoglobin (HbA1c) testing, which is essential for the long-term monitoring of blood glucose control in patients with diabetes. Rapid HbA1c measurement supports clinical decision-making during patient visits.

Coagulation Testing

The company addresses coagulation monitoring with products relevant to markers such as D-dimer, which is used in the assessment of thrombotic conditions including deep vein thrombosis and pulmonary embolism.

Thyroid and Hormone Testing

Micropoint Biotechnologies also develops assays for thyroid function and reproductive or fertility-related hormones, supporting endocrine assessment in near-patient settings.

Renal Function and Other Chemistry

Additional testing capabilities address renal function markers and other biochemistry parameters relevant to routine clinical management.

Instrumentation

Central to the company's offering are its immunoassay analyzers, which read the results of the corresponding test cartridges. These analyzers are typically designed to be compact, easy to operate, and suitable for use in a variety of settings ranging from emergency departments and intensive care units to smaller clinics and primary care facilities. The instruments provide quantitative digital readouts, connectivity options for data management, and streamlined workflows that require minimal technical training.

By offering multiple analyzer models with differing throughput and portability characteristics, the company aims to serve customers with varying testing volumes and space requirements. The analyzers are engineered to work exclusively with Micropoint's proprietary test kits, ensuring standardized performance and quality control.

Manufacturing and Quality

As an IVD manufacturer based in China, Micropoint Biotechnologies operates within a regulated environment governed by China's National Medical Products Administration (NMPA) for domestic products. Companies in this sector typically pursue quality management certifications such as ISO 13485, the international standard for medical device quality management systems, and CE marking for products intended for the European market. These frameworks are important for enabling both domestic sales and international export.

The company's manufacturing operations involve the production of both instrumentation and reagent consumables, requiring precision assembly, biological reagent formulation, and rigorous quality control to maintain assay accuracy and reproducibility.

Market and Applications

Micropoint Biotechnologies serves hospitals, clinics, laboratories, and other healthcare providers seeking rapid diagnostic capabilities. Its products are applicable across emergency medicine, cardiology, infectious disease management, chronic disease monitoring, and general clinical assessment. The appeal of POCT lies in reducing diagnostic turnaround time, improving patient throughput, and enabling more immediate clinical intervention.

The company participates in both the domestic Chinese market, which is one of the fastest-growing healthcare markets globally, and international markets where demand for affordable, reliable rapid diagnostics continues to expand. Distribution is typically handled through direct sales, distributor networks, and partnerships that extend the reach of its products across different regions.

Summary

Micropoint Biotechnologies Co., Ltd. is a point-of-care diagnostics company focused on immunoassay and rapid testing technologies. Its business centers on delivering integrated systems of analyzers and test kits that provide fast, quantitative results across clinical categories including cardiac markers, inflammation and infection markers, diabetes monitoring, coagulation, and hormone testing. Through its combination of instrumentation and consumables, the company supports healthcare providers in making timely, informed clinical decisions at or near the point of patient care.